The GLIDE trial aimed to assess the metabolic impact of the addition of a GLP-1 receptor agonist in the form of liraglutide 1.8 mg once daily following a LAGB in patients with T2DM. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.